Business Wire

Berlin’s First Smart City Quarter Powered by Panasonic

Share

Panasonic is proud to announce the start of its innovative, CO2-saving energy solution for the smart city project, Future Living®Berlin. The urban beacon is an important project in the company’s wider smart cities portfolio, which contribute to its focus on the decarbonization of society.

The installation in Berlin combines both green & sustainable and digital & connected living. It is realised through the installation of smart energy solutions including Panasonic’s highly efficient air to water heat pumps, photovoltaic (PV) panels and storage batteries integrated into an intelligent and efficient energy management system.

Junichi Suzuki, Chairman and CEO of Panasonic Europe B.V comments,

‘We bring to the project over 60 years of heating and cooling expertise alongside decades in PV and battery solutions, and a passion for innovations that will shape the future for generations to come. ‘

Panasonic has achieved strong sales growth in the relevant Energy business areas in Europe, e.g. double-digit sales growth in the air to water heat pump business for the last 10 years. The company has also committed in 2019 to grow the “Residential Energy Saving Equipment” business multiple times over by 2025.

Efficient Energy Management

For Panasonic, Future Living® Berlin is a fundamentally important experiment in building cutting-edge energy solutions. The project marks a milestone in achieving the goals set in the strategy.

Panasonic’s energy experts and software engineers of its R&D Centre in Europe have developed an intelligent energy management solution to optimize the use of energy and couple electricity with the heating sector. The smart control combines heat pumps together with other efficient, green Panasonic technologies, such as PV panels. The technologies have been integrated into an efficient energy saving solution not only controlled, but also constantly optimised by Panasonic’s intelligent energy management solution.

Ralf Becker, Project Leader Energy Group, Panasonic R&D Centre Europe explains,

‘The solution is a world first, developed with leading research institutions for decentralized energy management. In simulations together with university test labs we achieved an improvement of used energy by up to 15%.‘

A Beacon for Sustainable Living

The core energy component of the Future Living Berlin green & sustainable goal is the installed Panasonic’s air to water heat pump product line-up, ‘Aquarea’. A highly energy efficient technology, they run almost carbon-free when powered by the renewable energy provided by the 600 Panasonic HIT panels, which supply a capacity of 195kWp. On account of the patented silicone technology, the Panasonic photovoltaic system is 10% more efficient than conventional modules. Furthermore Panasonic’s HIT technology achieves a significantly better performance in hot environments because of its superior temperature coefficient – an essential advantage in coping with the climate change.

Utilising the renewable energy, the air to water system is used for space heating and warm water generation. For increased performance, the heat pumps include a cloud-based connectivity feature for installers called Aquarea Service Cloud which makes them even more reliable. It saves further CO2 emissions as maintenance visits can be organized much more efficiently and partly even conducted remotely.

These energy solutions are brought together under a Aquarea Smart Cloud, which allows end-users to monitor their power usage and manage temperature settings accordingly. This results in increased efficiency and comfort while enjoying transparency of their consumption.

To achieve further sustainable and green objectives, residents are part of a wider ecological environment which offers green car sharing, shared washing machines, and Panasonic energy solutions

Connected comfortability

The digital & connected goal of Future Living Berlin starts within the residential apartments. The equipment follows the idea of being smart and connected with Panasonic TVs and smart speakers being part of an overall IoT infrastructure, which includes an apartment manager as the central hub.

Digital & connected solutions are further extended to include wider security, safety, and smart building solutions that enhance the overall comfortability of residents.

Suzuki continues,

‘Future Living®Berlin is a future Way of Living – of how we may live tomorrow with a focus on social, digital & connected, and green & sustainable living.’

Panasonic is partnering in the smart city project with GSW Sigmaringen, the building-owner of Future Living® Berlin.

About Panasonic

Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 61.9 billion Euro (7.49 trillion yen) for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. To learn more about Panasonic: https://www.panasonic.com/global

IMAGES TO DOWNLOAD: https://www.flickr.com/photos/panasonic-europe/collections/72157714840244853/

Contact information

Tanya Houston
Wildwood PR Ltd
tanya.houston@wildwoodpr.com
Tel: +44 (0)1293 851115

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 12:55:00 CESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 12:00:00 CESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 09:30:00 CESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 08:00:00 CESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 07:00:00 CESTPress release

Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline ® Autogel ® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 07:00:00 CESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel®(lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatmen